Literature DB >> 12449718

Pulmonary function changes in long-term survivors of chronic myelogenous leukemia after allogeneic bone marrow transplantation: a Taiwan experience.

Tzeon-Jye Chiou1, Shiao-Lin Tung, Wei-Shu Wang, Woan-Fang Tzeng, Chueh-Chuan Yen, Frank S Fan, Jin-Hwang Liu, Po-Min Chen.   

Abstract

Pulmonary function in 42 patients with chronic myelogenous leukemia (CML) was tested before and after HLA-matched (39 related, 3 unrelated) allogeneic bone marrow transplantation (BMT) between 1985 and 1999. Pulmonary function tests (PFTs) including ventilatory capacity, lung volumes, and diffusion capacity for carbon monoxide (DLCO) were performed before and 3, 6, 12, and 24 months after BMT, and every 12 months thereafter. Possible pre- and post-BMT risk factors were evaluated for their influence on pulmonary function. Patients were divided into two groups according to their survival duration for more than 12 months or not. Pretransplant PFTs were essentially normal except for mild reduction in DLCO values in the short-term survival group. Overall pulmonary function changes revealed persistent and significant decrease of forced vital capacity (FVC) and DLCO values after BMT. The DLCO values reached abnormal levels (< 80%) and showed a trend of incomplete recovery. Decrease of forced expiratory volume in the first second (FEV1) and vital capacity were also noted but the FEV1/FVC ratio remained within normal limits after BMT. Transient fall of total lung capacity after BMT was noted. However, its values did not reach abnormal levels such as to cause restrictive ventilatory impairment. Possible risk factors including gender, smoking, bronchiolitis obliterans, acute and chronic graft-versus-host disease (GVHD) were found to have significant influences on posttransplant pulmonary function changes by multiple regression analysis. Most patients except those who developed bronchiolitis obliterans were clinically asymptomatic. Development of bronchiolitis obliterans was the most important factor to cause both clinical symptoms and impaired pulmonary function. In summary, pulmonary function changes before and after HLA-matched allogeneic BMT in long-term survivors of CML only showed modest dysfunction. The primary negative presentation with the development of oxygenation defect had no clinical significance in most patients. The influences on the impairment of pulmonary function were multifactorial.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12449718     DOI: 10.1081/cnv-120005900

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  6 in total

1.  Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant.

Authors:  A L Oh; P Patel; K Sweiss; R Chowdhery; S Dudek; D Rondelli
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  Clinical impact of pre-transplant pulmonary impairment on survival after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuhiko Kakihana; Kazuteru Ohashi; Yuka Hirashima; Yutaka Murata; Takeshi Kobayashi; Takuya Yamashita; Hisashi Sakamaki; Hideki Akiyama
Journal:  Pathol Oncol Res       Date:  2011-04-01       Impact factor: 3.201

3.  Lung function and long-term complications after allogeneic hematopoietic cell transplant.

Authors:  Eric C Walter; Mauricio Orozco-Levi; Alba Ramirez-Sarmiento; Afonso Vigorito; Paulo V Campregher; Paul J Martin; Mary E Flowers; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2009-10-17       Impact factor: 5.742

4.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

5.  Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors.

Authors:  Natasha A Jain; Priyanka A Pophali; Jeffrey K Klotz; Sawa Ito; Eleftheria Koklanaris; Kamna Chawla; Christopher S Hourigan; Nicole Gormley; Bipin N Savani; Austin John Barrett; Minoo Battiwalla
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-02       Impact factor: 5.742

Review 6.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.